Enhancing Chimeric Antigen Receptor T Cell Therapy by Modulating the p53 Signaling Network with Δ133p53α

Researchers showed that constitutive expression of Δ133p53α potentiated the anti-tumor activity of CD19-directed CAR T cells and limits dysfunction under conditions of high tumor burden and metabolic stress.